Acute and acute-on-chronic liver failure is a cause of death in patients suffering from viral hepatitis, and many cases need liver transplantation. Infection from hepatitis B virus may range from asymptomatic to severe acute and fulminant hepatitis. In this setting, treatment is mainly supportive as there is no consensus on antiviral therapy based on non-nucleoside reverse transcriptase inhibitors. Single-pass albumin dialysis is a liver-support technique for patients suffering from liver failure, that has shown effectiveness in the removal of both water-soluble and albumin-bound toxins, which accumulate due to impairment of the liver’s cleansing function. We report here the case of a 62-year-old male who presented with a severe acute hepatitis B infection, liver failure, and marked hyperbilirubinemia. Treatment with single-pass albumin dialysis combined with a hemoperfusion device was successful in improving clinical, physiological, and laboratory parameters.
LokASFMcMahonBJ.Chronic hepatitis B. Hepatology2007; 45(2): 507–539.
2.
WhalleySAMurrayJMBrownD, et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med2001; 193(7): 847–854.
3.
JindalAKumarMSarinSK.Management of acute hepatitis b and reactivation of hepatitis B. Liver Int2013; 33(Suppl 1): 164–175.
4.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu and European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol2017; 67(2): 370–398.
5.
MantzoukisKRodríguez-PerálvarezMBuzzettiE, et al. Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis. Cochrane Database Syst Rev2017;3(3): CD011645.
6.
BoonsriratUTiranathanagulKSrisawatN, et al. Effective bilirubin reduction by single-pass albumin dialysis in liver failure. Artif Organs2009; 33(8): 648–653.
7.
WeberVLinsbergerIHaunerM, et al. Neutral styrene divinylbenzene copolymers for adsorption of toxins in liver failure. Biomacromolecules2008; 9(4): 1322–1328.
8.
García MartínezJJBendjelidK. Artificial liver support systems: what is new over the last decade?Ann Intensive Care2018; 8: 109.
9.
TandonRFroghiS.Artificial liver support systems. J Gastroenterol Hepatol2021; 36(5): 1164–1179.
10.
RingeHVarnholtVZimmeringM, et al. Continuous veno-venous single-pass albumin hemodiafiltration in children with acute liver failure. Pediatr Crit Care Med2011; 12(3): 257–264.
11.
BenyoubKMullerMBonnetA, et al. Amounts of bile acids and bilirubin removed during single-pass albumin dialysis in patients with liver failure. Ther Apher Dial2011; 15(5): 504–506.
12.
PiechotaMPiechotaAMisztalM, et al. An evaluation of the usefulness of extracorporeal liver support techniques in patients with severe liver dysfunction. Arch Med Sci2019; 15(1): 99–112.
13.
KarvellasCJBagshawSMMcDermidRC, et al. A case-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. Blood Purif2009; 28(3): 151–158.
14.
SefferMTCottamDForniLG, et al. Heparin 2.0: a new approach to the infection crisis. Blood Purif2021; 50(1): 28–34.
15.
RifkinBSStewartIJ.Seraph-100 hemoperfusion in SARS-CoV-2-Infected patients early in critical illness: a case series. Blood Purif2022; 51: 317–320.
16.
SefferMTEdenGEngelmannS, et al. Elimination of Staphylococcus aureus from the bloodstream using a novel biomimetic sorbent haemoperfusion device. BMJ Case Rep2020; 13(8): e235262.
17.
ShriverZCapilaIVenkataramanG, et al. Heparin and heparan sulfate: analyzing structure and microheterogeneity. Handb Exp Pharmacol2012; (207): 159–176.
18.
HaoCXuHYuL, et al. Heparin: an essential drug for modern medicine. Prog Mol Biol Transl Sci2019; 163: 1–19.
19.
KielsteinJTBorchinaDNFühnerT, et al. Hemofiltration with the Seraph® 100 Microbind® affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients. Crit Care2021; 25(1): 190.
20.
PapeAKielsteinJTKrügerT, et al. Treatment of a critically ill COVID-19 patient with the Seraph 100 Microbind Affinity Filter. TH Open2021; 5(2): e134–e138.
21.
OlsonSWOliverJDCollenJ, et al. Treatment for severe coronavirus disease 2019 with the Seraph-100 Microbind Affinity Blood Filter. Crit Care Explore2020; 2: e0180.
22.
Mycroft-WestCSuDElliS, et al. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 receptor binding domain undergoes conformational change upon heparin binding. BioRxiv2020.
23.
FajnzylberJReganJCoxenK, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun2020; 11(1): 5493.
24.
SchulzeAGriponPUrbanS.Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology2007; 46: 1759–1768.
25.
MitznerSR.Extracorporeal liver support-albumin dialysis with the molecular adsorbent recirculating system (MARS). Ann Hepatol2011; 10 (Suppl 1): S21–S28.
26.
SponholzCMatthesKRuppD, et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure—a prospective, randomised crossover study. Crit Care2016; 20: 2.
27.
JiaJLiYWeiC, et al. Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection. Exp Ther Med2019; 17(6): 4730–4740.
